AnchorDx Reports First Patient Enrollment of UriFind Bladder Cancer Assay for Bladder Cancer in the US
- The company reported the first patient enrollment in a US trial of its UriFind bladder cancer assay in 1000+ patients with bladder cancer at 10 sites of Urology clinics and 3 CAP/CLIA laboratories
- The study focused to evaluate the noninvasive, quantitative real-time polymerase chain reaction (qPCR) assay to detect two DNA methylation biomarkers in urine specimens
- UriFind test is designed to provide improved sensitivity and specificity over cytology and other assays & provides advantages in the detection of early, micro, residual, and recurrent bladder cancer. The test has received CE certification in the EU & also received BTD from the US FDA in July 2021
Ref: PRNewswire | Image: AnchorDx
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.